Palisade Bio FY2030 EPS Cut by Brookline Capital Markets

Palisade Bio, Inc. (NASDAQ:PALI) – Investment analysts at Brookline Capital Markets cut their FY2030 earnings estimates for shares of Palisade Bio in a research report issued on Wednesday, May 20th. Brookline Capital Markets analyst K. Raja now anticipates that the company will post earnings of $0.41 per share for the year, down from their prior forecast of $0.50. The consensus estimate for Palisade Bio’s current full-year earnings is ($0.22) per share.

Palisade Bio (NASDAQ:PALI) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01).

A number of other equities research analysts have also issued reports on the stock. Wall Street Zen upgraded shares of Palisade Bio from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Weiss Ratings restated a “sell (e+)” rating on shares of Palisade Bio in a research note on Thursday, January 22nd. Wolfe Research initiated coverage on shares of Palisade Bio in a research note on Thursday, April 9th. They issued an “outperform” rating and a $7.00 target price on the stock. HC Wainwright initiated coverage on shares of Palisade Bio in a research note on Thursday, March 26th. They issued a “buy” rating and a $7.00 target price on the stock. Finally, Stifel Nicolaus initiated coverage on shares of Palisade Bio in a research note on Wednesday, February 25th. They issued a “buy” rating and a $5.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Palisade Bio currently has an average rating of “Moderate Buy” and an average target price of $10.20.

Palisade Bio Price Performance

Shares of PALI stock opened at $1.88 on Thursday. Palisade Bio has a 12 month low of $0.53 and a 12 month high of $2.86. The firm has a market capitalization of $326.33 million, a P/E ratio of -1.86 and a beta of 1.52. The company’s fifty day moving average price is $2.00 and its two-hundred day moving average price is $1.92.

Institutional Investors Weigh In On Palisade Bio

Several institutional investors and hedge funds have recently bought and sold shares of PALI. Cetera Investment Advisers acquired a new stake in Palisade Bio during the fourth quarter worth about $25,000. Schonfeld Strategic Advisors LLC acquired a new stake in Palisade Bio during the fourth quarter worth about $26,000. Virtu Financial LLC acquired a new stake in Palisade Bio during the fourth quarter worth about $28,000. Atom Investors LP acquired a new stake in Palisade Bio during the fourth quarter worth about $33,000. Finally, Barclays PLC bought a new position in Palisade Bio in the 4th quarter worth about $35,000. Institutional investors and hedge funds own 11.79% of the company’s stock.

About Palisade Bio

Palisade Bio, Inc is a clinical?stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll?like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.